⚠️ Vaping Likely Causes Lung and Oral Cancer — Most Definitive Review Yet

A landmark review led by UNSW Sydney has delivered the strongest verdict yet on e-cigarettes: nicotine vapes are likely to cause cancers of the lungs and oral cavity on their own — not just as a gateway to smoking.

Published in Carcinogenesis, the study examined over 100 studies since 2017. Unlike earlier work that compared vaping to smoking, this review focused exclusively on whether e-cigarettes cause cancer independently.

The evidence came from three converging directions:

🔹 Carcinogens identified in vape aerosols — volatile organic compounds and metals released by heating coils
🔹 Human biomarkers showing DNA damage, oxidative stress, and tissue inflammation in vapers
🔹 Mouse studies producing lung tumors from direct vape aerosol exposure
🔹 Case reports of unusually aggressive oral cancers in young, heavy vapers with no traditional risk factors

The numbers are striking: dual users (vape + smoke) face a four-fold higher lung cancer risk than smokers alone. Young people who start vaping are three times more likely to become regular cigarette smokers.

Important caveat: this is a review of existing evidence, not a long-term population study. Quantifying the exact cancer risk will take decades of epidemiological data. But the biological signals are already strong and consistent.

The historical parallel is sobering. It took nearly a century — from the mid-1800s to the 1964 US Surgeon General's report — to prove that smoking causes lung cancer. "E-cigarettes were introduced about 20 years ago. We should not wait another 80 years to decide what to do," said co-author A/Prof. Freddy Sitas.

For millions of young people who took up vaping believing it was harmless, this review changes the equation.

📄 Original paper (Carcinogenesis) · ScienceDaily

#Vaping #Cancer #PublicHealth #Science #Carcinogenesis

🧬 Scientists May Have Found a New Way to Mass-Produce Cancer-Fighting Immune Cells

For more than a decade, cancer immunotherapy has been dominated by T cells. CAR-T therapies can be powerful against some blood cancers, but they remain expensive, highly personalized, and much harder to use against solid tumors.

Now researchers at USC Stem Cell have shifted attention to a different immune lineage: granulocyte-monocyte progenitors, or GMPs — early precursor cells that can produce macrophages, the immune system’s “first responders.”

Macrophages are especially interesting because they naturally enter tumors, engulf abnormal cells, and help coordinate immune responses. But mature macrophages are difficult to grow in large numbers, hard to genetically engineer, and not ideal for freezing and storage.

The USC team worked one step earlier — with GMPs before they mature. Using a defined chemical cocktail, they managed to keep mouse and human GMPs in a progenitor-like state while allowing them to expand long-term in the lab. That is important because long-term self-renewal in the blood system was traditionally associated mainly with true hematopoietic stem cells, not more committed progenitors.

Then the researchers engineered these GMPs with CAR receptors so they could recognize cancer cells. They also added a CAR-Fc design that can recruit other immune cells and help activate broader anti-tumor responses.

In mouse experiments, the engineered GMPs settled into bone marrow and other blood-forming tissues, where they continuously generated tumor-infiltrating macrophages and other myeloid cells. The cells suppressed CD19-positive leukemia and HER2-positive solid tumors, and the dual CAR-Fc design showed stronger effects in allogeneic cancer models.

The same platform also restored antibacterial defense in mice with chronic granulomatous disease, an inherited immune deficiency disorder.

Why this matters: this is not just another CAR-T variant. It is a possible manufacturing breakthrough for an entirely different branch of the immune system — one that may be better suited for solid tumors and potentially easier to produce as an off-the-shelf therapy.

The important caveat: these are still preclinical results in mice. The real test will be whether the platform is safe, durable, and effective in humans.

But the idea is powerful: instead of only engineering mature immune cells, scientists may be learning how to grow a renewable upstream factory that keeps producing cancer-fighting cells from inside the body.

Paper: Cell
https://www.cell.com/cell/fulltext/S0092-8674(26)00643-4

Summary: ScienceDaily
https://www.sciencedaily.com/releases/2026/06/260620100317.htm

#Immunotherapy #Cancer #StemCells #CellTherapy #Biotech

🧬 A Personalized mRNA Cancer Vaccine Has Passed Its Biggest Test Yet

For the first time, a personalized mRNA cancer therapy has succeeded in a Phase 3 clinical trial — the final major testing stage before regulators can consider approval.

The treatment, called intismeran autogene, is not an off-the-shelf vaccine. Doctors sequence each patient’s tumour, identify mutations unique to their cancer, and manufacture an individual mRNA therapy encoding up to 34 of those tumour-specific targets. The goal is essentially to give the immune system a personalized wanted poster for the cancer.

In the trial, 1,137 people with stage IIB–IV melanoma whose tumours had been completely removed received either the personalized mRNA therapy plus the immunotherapy drug pembrolizumab (Keytruda), or pembrolizumab alone. The combination produced statistically significant and clinically meaningful improvements in both recurrence-free survival and distant-metastasis-free survival. No new safety signal was reported.

There is an important caveat: the companies have so far announced only top-line Phase 3 results. They have not yet released the detailed numbers, and it is not yet known whether the treatment ultimately extends overall survival. The therapy also remains investigational and has not been approved.

But the principle is now much harder to dismiss. Instead of finding one cancer vaccine that works for everyone, medicine may be able to manufacture a different vaccine for each individual tumour.

Cancer is personal.

The vaccine might have to be too.

#Cancer #mRNA #Melanoma #Immunotherapy #Biotechnology #Medicine #Science

🤖 AI Found 15 Cancers That Radiologists Had Missed

A new clinical study offers a glimpse of what medical AI may actually be best at: not replacing doctors, but quietly checking their work.

Researchers deployed an AI system called LiON alongside radiologists reading contrast-enhanced CT scans in routine hospital practice. In a prospective trial involving 10,333 patients, the system flagged 51 liver lesions that had initially been overlooked. Fifteen of them turned out to be malignant.

The alerts were not merely theoretical. They led doctors to amend 37 radiology reports, send 22 cases for multidisciplinary review, and change clinical management for some patients. Before the live trial, LiON had been trained on 6,443 patients and validated retrospectively on another 22,251.

The important nuance is that this was not a randomized trial comparing AI-assisted doctors against doctors alone, and the study did not show that the system improves survival. The researchers themselves say larger prospective comparative studies across different healthcare systems are still needed.

But this is a meaningful step beyond “AI beats doctors on a test set.”

Here, the algorithm sat inside an actual clinical workflow — and found cancers that humans had missed.

Perhaps the most useful medical AI will not be the doctor in the room.

It will be the second pair of eyes that never gets tired.

#AI #Medicine #Cancer #Radiology #MedicalAI #Science

https://www.nature.com/articles/s41591-026-04589-y⁠